Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis
Advances in Therapy · 2025
DOI: 10.1007/s12325-024-03096-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Shingo Kato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Saitama Medical Center, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Cost of Illness, Health Care Costs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: This retrospective claims analysis characterized contemporary ulcerative colitis (UC) treatment patterns and investigated the economic burden of UC in Japan. METHODS: This study used anonymized claims data in the Medical Data Vision database. Patients were included if they had a confirmed UC diagnosis and ≥ 1 claim of systemic treatment for UC (index date) between June 2018 and December 2022, in addition to continuous enrollment for ≥ 6 months before and ≥ 12 months after the index date. Patients were excluded if they were aged 90 days) and corticosteroid cycling (i.e., three or more ≥ 30-day corticosteroid courses over 1 year, with a ≥ 60-day gap between courses). RESULTS: Overall, 15,429 patients were included. The most frequently observed class of first-line treatment was 5-aminosalicylic acid monotherapy (75.0%); treatment modification was observed in 39.7% of patients. Within 1 year of follow-up, patients had a mean (SD) of 9.8 (6.8) outpatient visits, and a hospital stay was reported in 23.9% of patients. Mean total cost PPPM was ¥76,374. Of patients with ≥ 1 course of corticosteroids, 39.8% received suboptimal treatment with conventional therapies. HCRU and total costs were higher for patients with versus without suboptimal treatment with conventional therapies. CONCLUSIONS: Japanese patients with UC would benefit from treatment options that can reduce costs, HCRU, and suboptimal treatment with conventional therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Bristol Myers Squibb, London, UK.
- Bristol Myers Squibb, 1-2-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.
- Bristol Myers Squibb, Princeton, NJ, USA.
- Bristol Myers Squibb, 1-2-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan. ray.kim@bms.com.
ORCID-Profile: Shingo Kato, Bruno Casaes Teixeira, Thomas Laurent, Yoshiyuki Yamada, Hyunchung Kim
Zitieren
APA
Kato, S., Teixeira, B. C., Laurent, T., Yamada, Y., Dave, K., Shah, S., & Kim, H. (2025). Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis. Advances in Therapy. https://doi.org/10.1007/s12325-024-03096-1
Vancouver
Kato S, Teixeira BC, Laurent T, Yamada Y, Dave K, Shah S, et al. Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis. Advances in Therapy. 2025. doi:10.1007/s12325-024-03096-1
BibTeX
@article{Kato2025,
author = {Kato, Shingo and Teixeira, Bruno Casaes and Laurent, Thomas and Yamada, Yoshiyuki and Dave, Kiran and Shah, Shweta and Kim, Hyunchung},
title = {Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-024-03096-1}
}
EUVIMED